Filing Flows › AbCellera Biologics (ABCL) › Guidance & outlook

AbCellera Biologics (ABCL) guidance and outlook

AbCellera Biologics' 10-Q filed Nov 9, 2026 makes 27 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 9, 2026

• • our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if these markets achieve the forecasted growth, our drug candidates may fail to achieve sufficient market acceptance or adoption;
• • our ability to achieve projected discovery, preclinical development, and clinical milestones for our internal programs, including data from the Phase 2 trial for ABCL635, as well as our partners’ ability to achieve projected discovery and development milestones and other anticipated key events, including commercial sales resulting in royalties owed to us, in the expected timelines or at all;
• • our ability to leverage our full platform capabilities - from target identification to Investigational New Drug (“IND”) application submission and to clinical development - to advance our internal pipeline of drug candidates, as well as to support our partners;
• We aim to build a competitive advantage in bringing antibody drugs candidates from target into clinical testing by combining expertise, technologies, and infrastructure to build integrated capabilities for antibody drug discovery and development .
• We expect to continue to make significant investments in this area for the foreseeable future and expect to continue to incur significant expenses in connection with our ongoing activities, including as we:
• We expect to initiate late-stage development of ABCL635 for menopausal VMS in 2027.
• At present, we do not intend to pursue development past Phase 1.
• Under the terms of the agreement, we will lead discovery and early development activities, and Vertex will fund all research and development costs while retaining the right to develop and commercialize resulting therapeutic multispecific antibodies.
• We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by multiple factors as described below, each of which presents growth opportunities for our business.
• As our discovery and development capabilities have matured, we are increasingly in a position to pursue attractive, well-validated targets ourselves, e.g. in the GPCR, ion channel, and TCE spaces.
• We plan on investing significant resources in the preclinical and clinical development of internal programs that will impact our financial results.
• We intend to allocate resources to the design and execution of these clinical trials, which represent a substantial and ongoing commitment of capital and personnel.

AbCellera Biologics' latest quarter

Questions

What does AbCellera Biologics expect?

• our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if these markets achieve the forecasted growth, our drug candidates may fail to achieve sufficient market acceptance or adoption; • our ability to achieve projected discovery, preclinical development, and clinical milestones for our internal programs, including data from the Phase 2 trial for ABCL635, as well as our partners’ ability to achieve projected discovery and development milestones and other anticipated key events, including commercial sales resulting in royalties owed to us, in t

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.